The First Close, Adjuvant Capital

July 6, 2021
Jessica Straus

We interviewed Jenny Yip, managing partner at Adjuvant Capital, a life sciences venture capital firm based in New York and San Francisco.  Adjuvant Capital launched in 2019 and announced its first, $300M fund in February 2021 to invest in medical innovations in historically overlooked market segments. 

When Jenny Yip was fourteen years old, she attended a job fair where she met a representative from Doctors Without Borders, which sparked her interest in global health. Going into college, she pictured herself graduating with a pre-med degree and becoming a physician. However, a summer internship at Goldman Sachs steered her path away from medicine and into investment banking.

Jenny spent a decade at Goldman Sachs building both her investment acumen and nurturing her passion for global health. She requested a secondment from Goldman Sachs to volunteer for TechnoServe, an NGO in Nairobi, Kenya, where she provided consulting services for farmers and small business owners around Kenya. Eventually, an opportunity arose at the Gates Foundation for Jenny to be part of its strategic investment fund. At the Gates Foundation, Jenny was able to combine her passions for public health, impact, and investing. From this foundation, she helped to launch Adjuvant Capital with a mission to prioritize global health. 

In this episode of The First Close, we cover: 

  • Jenny’s early career as an investment banker for Goldman Sachs

  • The global experiences and passion for healthcare that led Jenny to start her own fund

  • Adjuvant Capital’s approach to addressing issues in public health

  • Using the “but-for” test to weigh the impact of a potential investment

Listen to our interview with Jenny by streaming The First Close on Apple Podcasts and Spotify

DISCLOSURE: This publication contains general information only and eShares, Inc. dba Carta, Inc. (“Carta”) is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services.  This publication is not a substitute for such professional advice or services nor should it be used as a basis for any decision or action that may affect your business or interests.  Before making any decision or taking any action that may affect your business or interests, you should consult a qualified professional advisor.  This communication is not intended as a recommendation, offer or solicitation for the purchase or sale of any security. Carta does not assume any liability for reliance on the information provided herein.